Cogent Biosciences, Inc. Common Stock
COGT
$42.84
+10.24%
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, primarily targeting the KIT D816V mutation in Systemic Mastocytosis (SM) and exon 17 mutations in gastrointestinal stromal tumors (GIST). As a clinical-stage precision oncology player, it differentiates itself through its selective tyrosine kinase inhibitor, bezuclastinib (CGT9486), designed to potently inhibit key driver mutations. The current investor narrative centers on the FDA's acceptance of its New Drug Application for bezuclastinib in SM, a major de-risking event that sets up a potential approval decision in 2026 and has driven significant stock appreciation. Debate remains around the drug's commercial potential and the company's path to profitability as it transitions from a development-stage to a commercial-stage biotech.…
COGT
Cogent Biosciences, Inc. Common Stock
$42.84
Related headlines
COGT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cogent Biosciences, Inc. Common Stock's 12-month outlook, with a consensus price target around $54.25 and implied upside of +26.6% versus the current price.
Average Target
$54.25
0 analysts
Implied Upside
+26.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$35 - $72
Analyst target range
Cogent Biosciences is covered by 12 analysts, with a consensus recommendation of 'Strong Buy' (mean recommendation 1.46 on a 1-5 scale). The average price target is $54.25, implying 36.4% upside from the current price of $39.76. The distribution leans heavily bullish, with no sell ratings and only a few hold ratings (e.g., Needham at Hold, Baird at Neutral). The high target of $72.00 assumes successful drug approval, rapid market penetration, and potential multiple expansion as the company transitions to a commercial-stage biotech. The low target of $35.00 prices in risks such as regulatory delays, competitive pressure, or slower-than-expected adoption, representing a 12% downside from current levels. The wide spread between low and high ($35 to $72) reflects high uncertainty typical of pre-revenue biotech stocks. Recent ratings actions have been uniformly positive, with firms like Wedbush, HC Wainwright, and Piper Sandler reiterating Outperform/Buy ratings in 2026. The absence of downgrades suggests analyst confidence remains intact following the FDA acceptance, though the wide target range indicates that outcomes are highly binary.
Bulls vs Bears: COGT Investment Factors
Cogent Biosciences presents a high-conviction bull case centered on the FDA's acceptance of bezuclastinib's NDA, strong analyst support with 36% upside to the average target, and the potential to generate billions in revenue from a currently zero-revenue base. However, the bear case is equally compelling: the company is pre-revenue with widening losses, negative free cash flow, and a binary outcome tied to regulatory approval. The single most important tension is whether bezuclastinib receives FDA approval in 2026 and achieves commercial adoption. If approved, the stock could re-rate significantly toward the $72 high target; if denied or delayed, the stock could fall to the $10.38 low. Currently, the bull case has stronger evidence given the FDA acceptance and analyst consensus, but the risk-reward is asymmetric with substantial downside if the binary event fails.
Bullish
- FDA Acceptance De-risks Approval Path: The FDA accepted Cogent's New Drug Application for bezuclastinib in Systemic Mastocytosis, setting a PDUFA date in 2026. This regulatory milestone validates the clinical package and reduces binary risk, as FDA acceptance implies the application is sufficiently complete for review.
- Strong Analyst Consensus with 36% Upside: The stock has a consensus 'Strong Buy' rating from 12 analysts, with an average price target of $54.25, implying 36.4% upside from the current $39.76. The high target of $72 suggests potential for 81% gains if commercial execution exceeds expectations.
- Massive Revenue Growth Potential: Analysts estimate average revenue of $1.74 billion by 2027, with a high estimate of $3.29 billion. This represents a transition from zero revenue to a potential blockbuster drug, driving significant enterprise value creation.
- Strong Balance Sheet with Low Debt: Cogent has $241.6 million in cash and a current ratio of 14.2, providing ample runway to fund operations through the approval decision. Debt-to-equity is low at 0.40, reducing financial distress risk.
Bearish
- Pre-Revenue with Widening Losses: Cogent reported $0 revenue and a net loss of $97.4 million in Q1 2026, up from $72.0 million in Q1 2025. Operating expenses are running at $102.5 million per quarter, and free cash flow was negative $87.3 million in Q1, indicating cash burn is accelerating.
- Binary Outcome Dependent on Approval: The entire investment thesis hinges on FDA approval of bezuclastinib. Any regulatory delay, complete response letter, or safety signal could cause the stock to collapse toward the 52-week low of $10.38, representing a 74% downside from current levels.
- High Valuation with No Earnings Visibility: With a trailing PE of -13.9 and forward PE of -42.1, the stock trades at extreme multiples relative to earnings. The price-to-book ratio of 3.77, while below the industry average of ~4.5, still implies significant premium for a pre-revenue company.
- Dilution Risk from Equity Financing: Cogent raised $469.4 million through common stock issuance in Q4 2025, significantly increasing share count. The company's reliance on external capital to fund negative free cash flow of -$286 million TTM raises the risk of further dilution, pressuring EPS.
COGT Technical Analysis
Cogent Biosciences is in a strong uptrend, with the stock up 226.2% over the past year, dramatically outperforming the S&P 500's 16.5% gain. The current price of $39.76 sits at 90.9% of its 52-week range ($10.38–$43.73), indicating the stock is near its highs and reflecting strong bullish momentum. This positioning near the top of the range suggests the market is pricing in positive catalysts, but also leaves the stock vulnerable to profit-taking if news disappoints. Short-term momentum is positive but decelerating: the stock gained 5.9% over the past month and 8.0% over the past three months, both outpacing the S&P 500's 0.8% and 3.5% gains, respectively. However, the 1-month gain is less than the 3-month gain, suggesting a slight loss of upside velocity. The relative strength indicators (1-month RS of 5.2, 3-month RS of 4.5) confirm the stock is outperforming the market but at a moderating pace. Key support lies at the 52-week low of $10.38, while resistance is at the 52-week high of $43.73. A breakout above $43.73 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below recent support near $35 could indicate a trend reversal. The stock's beta of 0.34 indicates it is significantly less volatile than the market, which is unusual for a small-cap biotech and may reflect the stock's strong directional move with low correlation to broad market swings.
Beta
0.33
0.33x market volatility
Max Drawdown
-26.3%
Largest decline past year
52-Week Range
$10-$44
Price range past year
Annual Return
+255.5%
Cumulative gain past year
| Period | COGT Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +3.6% |
| 3m | +19.4% | +5.1% |
| 6m | +20.0% | +13.8% |
| 1y | +255.5% | +22.2% |
| ytd | +23.3% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COGT Fundamental Analysis
Cogent Biosciences is a pre-revenue biotechnology company with no product sales, reporting $0 in revenue for the most recent quarter (Q1 2026) and all prior periods. The company's growth trajectory is entirely dependent on the successful commercialization of bezuclastinib, with analysts estimating average revenue of $1.74 billion by 2027, though estimates range widely from $583 million to $3.29 billion. The lack of current revenue means the investment case hinges entirely on the drug's approval and market adoption, making it a high-risk, high-reward binary event. The company is deeply unprofitable, reporting a net loss of $97.4 million in Q1 2026, compared to $72.0 million in Q1 2025, indicating losses are widening as it scales up pre-commercial activities. Gross margin is negative (gross profit of -$1.2 million in Q1 2026) due to cost of revenue exceeding zero revenue, which is typical for pre-commercial biotechs. Operating expenses totaled $102.5 million in Q1 2026, with R&D of $75.4 million and SG&A of $28.2 million, reflecting heavy investment in clinical trials and building a commercial infrastructure. The company's balance sheet shows a current ratio of 14.2, indicating ample liquidity to fund operations, with $241.6 million in cash at the end of Q1 2026. However, free cash flow was negative $87.3 million in Q1 2026, and the company has relied on equity and debt financing, including a $469.4 million common stock issuance in Q4 2025. Debt-to-equity is low at 0.40, but the negative free cash flow and reliance on external capital raise concerns about dilution and financial sustainability if approval or commercial launch is delayed.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-286272000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COGT Overvalued?
Since net income is negative, we use the price-to-sales (PS) ratio for valuation; however, with zero revenue, the PS ratio is undefined (0). Therefore, we instead evaluate the price-to-book (PB) ratio, which is 3.77, and the negative earnings-based multiples. The trailing PE is -13.9 and forward PE is -42.1, reflecting the company's lack of profitability and the market's expectation of future earnings. The wide gap between trailing and forward PE (more negative forward) implies that analysts expect losses to persist or widen in the near term before profitability is achieved. Compared to the biotechnology industry average PB of roughly 4.5 (estimated), Cogent's PB of 3.77 is at a 16% discount, suggesting the market is not yet pricing in a significant premium for its pipeline. However, this discount may be justified by the company's pre-revenue status and high cash burn. Historically, Cogent's PB ratio has ranged from 1.4 to 5.4 over the past five years, with the current 3.77 near the middle of that range. This suggests the stock is not excessively overvalued relative to its own history, but the valuation is highly dependent on the success of bezuclastinib. The current PB is below the Q3 2025 peak of 5.4, indicating some multiple compression as the market awaits commercial execution.
PE
-13.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-7.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cogent's financial profile is typical of a pre-commercial biotech but carries significant risks. The company reported $0 revenue and a net loss of $97.4 million in Q1 2026, with losses widening 35% year-over-year from $72.0 million. Operating expenses are running at $102.5 million per quarter, with R&D of $75.4 million and SG&A of $28.2 million, reflecting heavy investment ahead of a potential launch. Free cash flow was negative $87.3 million in Q1, and TTM free cash flow is -$286 million, indicating the company is burning through cash rapidly. While the current ratio of 14.2 and $241.6 million cash provide near-term liquidity, the company will likely need additional financing, which could cause dilution. The debt-to-equity ratio of 0.40 is manageable, but negative equity (due to accumulated deficits) means the company is technically insolvent on a book value basis, though this is common for biotechs.
Market & Competitive Risks: Cogent's valuation is highly sensitive to binary regulatory events. The stock trades at a price-to-book of 3.77, a 16% discount to the biotech industry average of ~4.5, but this discount may reflect the pre-revenue status. The trailing PE of -13.9 and forward PE of -42.1 indicate the market expects continued losses. The stock's beta of 0.34 is unusually low for a small-cap biotech, suggesting low correlation with broad market moves, but this could change if macro conditions shift. Competitive risk is high: Novartis' Ayvakit (avapritinib) is already approved for SM, and Cogent must demonstrate differentiation. The wide analyst target range ($35 to $72) reflects high uncertainty. Recent news of FDA acceptance is positive, but any regulatory setback could trigger a sharp sell-off.
Worst-Case Scenario: The most damaging scenario would be the FDA issuing a Complete Response Letter for bezuclastinib, citing safety or efficacy concerns, or requiring additional trials. This would likely cause the stock to collapse to the 52-week low of $10.38, representing a 74% decline from the current price of $39.76. Additionally, if a competitor's drug shows superior efficacy or if Cogent's cash burn forces a dilutive financing at a depressed stock price, the downside could be even greater. The historical max drawdown of -26.34% is mild compared to the potential binary risk, which could result in a loss of over 70% for investors buying at current levels.